▁British 8.59375
▁Bi 8.046875
ote 1.81640625
ch 0.12213134765625
' 5.16796875
s 0.00858306884765625
▁Can 5.8984375
cer 0.04095458984375
▁D 1.435546875
rug 0.01163482666015625
▁Sh 3.03515625
ows 0.058746337890625
▁Pos 2.52734375
itive 0.005413055419921875
▁Results 0.75439453125
▁but 7.37890625
▁Anal 5.18359375
yst 0.0034542083740234375
s 0.1385498046875
▁Ur 4.8046875
ge 0.0106353759765625
▁Ca 0.181640625
ution 0.0002014636993408203
<0x0A> 0.09271240234375
L 4.88671875
ON 0.318603515625
D 0.0002727508544921875
ON 0.0001685619354248047
▁— 3.87890625
▁British 1.337890625
▁bi 0.96484375
ote 0.0255279541015625
chn 1.126953125
ology 0.0008072853088378906
▁company 0.436767578125
, 3.8671875
▁Med 4.38671875
Cell 9.328125
▁Th 3.578125
era 0.00026702880859375
pe 0.001255035400390625
ut 0.00013959407806396484
ics 0.00968170166015625
, 0.60546875
▁announced 1.841796875
▁positive 1.865234375
▁results 0.326171875
▁in 3.052734375
▁their 4.4375
▁latest 2.59375
▁clin 1.1298828125
ical 0.00197601318359375
▁trial 0.330810546875
▁for 1.298828125
▁their 1.15625
▁innov 5.48046875
ative 0.006317138671875
▁cancer 0.60791015625
▁drug 0.36328125
, 0.60400390625
▁On 4.7109375
col 3.1015625
yn 4.671875
, 1.5478515625
▁yesterday 3.6484375
. 0.325439453125
▁The 1.3583984375
▁drug 1.484375
' 4.73046875
s 0.0004382133483886719
▁encourag 6.2265625
ing 0.0006227493286132812
▁performance 2.259765625
▁in 1.28515625
▁tre 2.337890625
ating 0.00031495094299316406
▁advanced 2.59375
▁forms 3.9921875
▁of 0.0031757354736328125
▁lung 3.361328125
▁cancer 0.25537109375
, 2.470703125
▁combined 3.775390625
▁with 0.0090484619140625
▁its 1.669921875
▁relatively 2.71875
▁low 0.413330078125
▁side 2.001953125
▁effects 0.49267578125
, 0.475830078125
▁have 2.59375
▁generated 3.9921875
▁considerable 2.95703125
▁excitement 1.4267578125
▁among 1.5087890625
▁do 5.08984375
ctors 0.0006260871887207031
▁and 0.277099609375
▁patients 1.9716796875
▁al 0.49169921875
ike 6.318092346191406e-06
. 0.2054443359375
▁However 1.9970703125
, 0.0157318115234375
▁anal 1.3193359375
yst 0.0016956329345703125
s 0.007343292236328125
▁are 1.5087890625
▁ur 1.115234375
ging 0.0005884170532226562
▁ca 0.049041748046875
ution 7.331371307373047e-05
, 1.1572265625
▁as 1.8857421875
ser 4.18359375
ting 0.0002727508544921875
▁that 0.03216552734375
▁further 1.888671875
▁investigation 4.44140625
▁is 0.41455078125
▁required 1.5048828125
▁before 0.406982421875
▁definit 4.5859375
ive 0.00927734375
▁conclus 0.138427734375
ions 0.0003936290740966797
▁can 0.08294677734375
▁be 0.00243377685546875
▁drawn 0.39892578125
▁about 2.14453125
▁the 0.2408447265625
▁drug 0.2081298828125
' 0.06341552734375
s 8.606910705566406e-05
▁effic 1.0380859375
acy 0.0006437301635742188
▁and 2.21484375
▁long 3.2890625
- 0.097412109375
term 0.0021343231201171875
▁effects 3.619140625
. 0.08856201171875
<0x0A> 0.0653076171875
In 3.66796875
▁the 0.59716796875
▁phase 4.453125
▁II 0.82763671875
▁clin 1.0654296875
ical 0.00021886825561523438
▁trial 0.0345458984375
, 0.233154296875
▁On 1.208984375
col 0.0214080810546875
yn 0.0008120536804199219
▁exhib 5.84765625
ited 0.00139617919921875
▁prom 2.658203125
ising 0.0004119873046875
▁out 3.935546875
comes 0.0005326271057128906
▁in 0.61669921875
▁patients 2.2109375
▁with 0.337158203125
▁stage 2.84375
▁IV 1.294921875
▁non 0.474609375
- 0.0153961181640625
small 0.01041412353515625
▁cell 0.09552001953125
▁lung 0.018035888671875
▁cancer 0.0382080078125
▁( 0.5302734375
NS 0.006549835205078125
CLC 0.003795623779296875
). 0.828125
▁The 0.7939453125
▁study 2.8125
▁involved 2.279296875
▁ 0.1876220703125
3 1.8134765625
5 2.44140625
0 4.74609375
▁patients 0.318115234375
▁who 1.255859375
▁were 0.859375
▁random 3.138671875
ized 0.3828125
▁to 0.366943359375
▁receive 0.2105712890625
▁either 0.197998046875
▁On 0.46044921875
col 0.00484466552734375
yn 0.0004782676696777344
▁or 0.277587890625
▁a 0.98583984375
▁place 0.59130859375
bo 6.389617919921875e-05
▁in 2.501953125
▁combination 0.81005859375
▁with 0.0005121231079101562
▁standard 1.0498046875
▁chem 0.3408203125
other 0.0056915283203125
apy 0.022705078125
. 0.498291015625
▁Although 5.9140625
▁specific 8.71875
▁data 1.41015625
▁on 1.55078125
▁patient 3.224609375
▁out 0.98583984375
comes 7.736682891845703e-05
▁have 1.9140625
▁not 0.48388671875
▁been 1.3251953125
▁dis 2.35546875
closed 0.004344940185546875
, 0.20166015625
▁Med 1.6689453125
Cell 0.033721923828125
▁reported 2.787109375
▁that 0.2022705078125
▁On 3.275390625
col 0.00672149658203125
yn 0.00043201446533203125
▁demonstrated 1.91796875
▁a 0.7255859375
▁statist 1.697265625
ically 8.547306060791016e-05
▁significant 0.0166168212890625
▁improvement 0.5244140625
▁in 0.10650634765625
▁overall 0.796875
▁response 1.869140625
▁rate 0.19873046875
▁and 1.7099609375
▁pro 0.62451171875
gression 0.00034046173095703125
- 0.0489501953125
free 0.0006823539733886719
▁surv 0.0038089752197265625
ival 9.262561798095703e-05
, 2.681640625
▁compared 0.837890625
▁to 0.08782958984375
▁the 0.309326171875
▁control 1.513671875
▁group 0.12005615234375
. 0.0233917236328125
<0x0A> 0.28173828125
Dr 3.376953125
. 0.0701904296875
▁Elizabeth 6.15234375
▁Thompson 6.1796875
, 0.0264739990234375
▁a 1.4482421875
▁ren 2.53125
owned 0.0004639625549316406
▁on 0.26953125
colog 0.068359375
ist 0.0007786750793457031
▁at 0.90576171875
▁The 4.4375
▁Royal 1.6123046875
▁Mars 0.44921875
den 0.0005602836608886719
▁Hospital 0.2890625
, 0.916015625
▁expressed 3.451171875
▁her 0.29296875
▁enthus 0.87255859375
ias 0.0014448165893554688
m 2.8967857360839844e-05
▁regarding 4.10546875
▁these 2.6484375
▁inter 8.3515625
im 0.0012311935424804688
▁find 1.7353515625
ings 4.649162292480469e-06
. 1.06640625
▁" 0.4580078125
The 1.208984375
▁pre 2.939453125
lim 0.01410675048828125
inary 0.00015032291412353516
▁results 0.66015625
▁of 1.19921875
▁this 0.68896484375
▁trial 0.84423828125
▁are 0.53271484375
▁genu 9.578125
in 0.00135040283203125
ely 3.933906555175781e-06
▁exc 0.8349609375
iting 6.67572021484375e-06
. 1.8369140625
▁To 5.56640625
▁witness 5.49609375
▁a 1.6484375
▁new 3.09375
▁drug 0.94677734375
▁show 2.984375
▁such 0.297607421875
▁potential 3.2734375
▁in 0.52978515625
▁an 4.25390625
▁ag 3.4375
gress 0.0004260540008544922
ive 0.00171661376953125
▁form 0.794921875
▁of 0.0005407333374023438
▁cancer 0.466552734375
▁like 2.556640625
▁NS 0.242919921875
CLC 0.0006842613220214844
▁is 0.1043701171875
▁an 3.345703125
▁incred 0.97802734375
ible 0.3818359375
▁step 3.861328125
▁forward 0.042572021484375
▁in 1.4365234375
▁the 0.7236328125
▁search 4.4296875
▁for 0.003124237060546875
▁more 1.4853515625
▁effective 0.0465087890625
▁treat 0.461669921875
ments 2.014636993408203e-05
," 0.966796875
▁she 0.1702880859375
▁said 0.350830078125
. 0.10992431640625
▁L 10.4375
ung 0.5029296875
▁cancer 0.0133819580078125
, 3.5390625
▁she 3.66796875
▁noted 2.416015625
, 0.003223419189453125
▁is 0.61669921875
▁the 0.974609375
▁leading 0.75537109375
▁cause 0.0135955810546875
▁of 0.00016200542449951172
▁cancer 0.051483154296875
▁death 0.8125
s 1.107421875
▁world 0.497314453125
wide 0.0002961158752441406
, 0.34423828125
▁thus 8.1015625
▁any 0.90087890625
▁adv 1.4990234375
ances 0.81689453125
▁in 0.1416015625
▁its 1.5654296875
▁treatment 0.1324462890625
▁are 0.33544921875
▁greatly 3.5
▁anticip 2.375
ated 5.733966827392578e-05
. 0.450439453125
<0x0A> 0.038482666015625
However 1.546875
, 0.0004584789276123047
▁ca 3.49609375
ution 0.01090240478515625
▁is 1.69140625
▁war 1.0673828125
r 6.0439109802246094e-05
anted 8.821487426757812e-06
, 1.52734375
▁given 2.86328125
▁the 0.70654296875
▁pre 3.0625
lim 0.039947509765625
inary 0.0006089210510253906
▁nature 0.0272979736328125
▁of 0.0009169578552246094
▁these 0.80029296875
▁results 1.1171875
. 0.304931640625
▁Anal 3.525390625
yst 0.00621795654296875
s 0.0143585205078125
▁emphas 3.34375
ize 0.24462890625
▁the 1.845703125
▁need 0.50146484375
▁for 0.006561279296875
▁additional 2.62890625
▁data 3.2734375
▁from 2.31640625
▁a 2.8828125
▁larger 0.318359375
, 1.4453125
▁random 1.513671875
ized 0.005710601806640625
, 1.6923828125
▁phase 1.8271484375
▁III 0.00992584228515625
▁clin 0.9248046875
ical 3.147125244140625e-05
▁trial 0.007778167724609375
▁to 1.279296875
▁cor 4.265625
ro 4.863739013671875e-05
bor 0.00011813640594482422
ate 2.5987625122070312e-05
▁the 0.7529296875
▁initial 2.830078125
▁find 0.06427001953125
ings 1.5497207641601562e-06
. 0.361572265625
▁Ob 8.2109375
ser 0.8876953125
vers 0.61572265625
▁have 2.291015625
▁pointed 2.673828125
▁out 0.2200927734375
▁that 0.061920166015625
▁several 4.96875
▁cancer 4.2421875
▁dru 0.17626953125
gs 3.5762786865234375e-07
▁in 2.37109375
▁the 0.379638671875
▁past 0.07293701171875
▁have 0.1141357421875
▁demonstrated 1.84765625
▁encourag 2.9296875
ing 0.00010788440704345703
▁results 0.63916015625
▁in 0.10662841796875
▁phase 3.013671875
▁II 0.032867431640625
▁tri 0.271240234375
als 4.0531158447265625e-06
▁but 1.6064453125
▁failed 0.8759765625
▁to 0.02960205078125
▁gain 7.50390625
▁regul 1.310546875
atory 0.00040912628173828125
▁appro 0.002704620361328125
val 8.702278137207031e-06
▁due 1.2744140625
▁to 0.0009436607360839844
▁ins 2.34375
u 0.0122222900390625
fficient 0.00673675537109375
▁effic 2.115234375
acy 2.7894973754882812e-05
▁or 1.02734375
▁un 2.28515625
for 3.5546875
ese 8.893013000488281e-05
en 0.0023040771484375
▁side 0.6259765625
▁effects 0.00547027587890625
▁in 0.65771484375
▁further 5.46484375
▁studies 1.30078125
. 0.00974273681640625
<0x0A> 0.2374267578125
More 3.306640625
over 0.02764892578125
, 0.0001302957534790039
▁the 1.796875
▁long 3.89453125
- 0.005405426025390625
term 0.0005640983581542969
▁effects 1.1240234375
▁of 0.0223236083984375
▁On 0.09393310546875
col 0.00916290283203125
yn 0.00011682510375976562
, 2.77734375
▁especially 1.826171875
▁in 1.2060546875
▁terms 1.7529296875
▁of 0.00013697147369384766
▁surv 4.1640625
ival 0.00909423828125
▁rates 0.8740234375
, 0.615234375
▁remain 0.81298828125
▁unknown 1.359375
. 0.12939453125
▁Additionally 5.69921875
, 0.0003170967102050781
▁the 1.0419921875
▁phase 7.93359375
▁II 0.34033203125
▁trial 0.216064453125
▁only 2.37890625
▁involved 1.3955078125
▁patients 0.3408203125
▁with 0.11981201171875
▁advanced 0.78857421875
▁NS 0.8466796875
CLC 0.00013685226440429688
, 0.26416015625
▁limit 3.51171875
ing 1.537799835205078e-05
▁the 0.67333984375
▁drug 0.97705078125
' 0.005214691162109375
s 4.184246063232422e-05
▁potential 0.994140625
▁impact 3.79296875
▁on 0.2093505859375
▁other 1.2578125
▁tum 7.01171875
or 0.220947265625
▁types 0.041900634765625
. 0.185546875
▁Further 3.2578125
▁research 1.0234375
▁needs 5.79296875
▁to 0.0006961822509765625
▁be 0.1865234375
▁conducted 0.2354736328125
▁to 0.2357177734375
▁as 3.271484375
certain 3.9577484130859375e-05
▁the 0.79541015625
▁drug 0.2900390625
' 0.0022869110107421875
s 3.0279159545898438e-05
▁effic 0.4013671875
acy 1.5497207641601562e-05
▁in 0.54736328125
▁other 1.466796875
▁forms 1.4462890625
▁of 0.002960205078125
▁lung 1.9716796875
▁cancer 0.023406982421875
▁and 0.7724609375
▁different 6.46484375
▁stages 1.8994140625
▁of 0.1109619140625
▁disease 1.6015625
▁pro 1.3515625
gression 0.0008287429809570312
. 0.07421875
<0x0A> 0.027984619140625
Des 1.4580078125
p 0.00012183189392089844
ite 1.1086463928222656e-05
▁the 2.119140625
▁res 2.83984375
erv 0.0066070556640625
ations 6.079673767089844e-06
, 1.0302734375
▁financial 9.96875
▁mark 1.6240234375
ets 0.00014781951904296875
▁have 0.80224609375
▁respond 1.181640625
ed 4.76837158203125e-05
▁posit 0.173583984375
ively 4.887580871582031e-06
▁to 0.021636962890625
▁Med 2.314453125
Cell 0.03472900390625
▁Th 4.30078125
era 3.647804260253906e-05
pe 6.031990051269531e-05
ut 6.794929504394531e-06
ics 0.02264404296875
' 0.058258056640625
▁announ 0.37451171875
cement 0.00635528564453125
, 0.95556640625
▁with 0.2108154296875
▁the 0.54541015625
▁company 0.135986328125
' 0.01055145263671875
s 0.00031828880310058594
▁stock 1.201171875
▁so 3.716796875
aring 0.00028634071350097656
▁by 0.54443359375
▁almost 3.478515625
▁ 0.0272674560546875
3 2.04296875
0 0.1304931640625
%. 1.5927734375
▁In 2.7578125
vest 0.07757568359375
ors 0.03564453125
▁are 0.89501953125
▁bu 5.046875
oy 0.01261138916015625
ed 0.0163116455078125
▁by 0.0009236335754394531
▁the 0.05755615234375
▁potential 1.203125
▁of 0.439697265625
▁On 0.1220703125
col 0.0025539398193359375
yn 0.00015819072723388672
▁to 0.87255859375
▁dis 3.599609375
rupt 0.02069091796875
▁the 0.047760009765625
▁lung 4.84765625
▁cancer 0.0008587837219238281
▁treatment 0.439697265625
▁landscape 0.3701171875
, 0.640625
▁which 1.28515625
▁is 0.93603515625
▁anticip 6.82421875
ated 0.0038471221923828125
▁to 0.00406646728515625
▁reach 1.5732421875
▁a 2.056640625
▁market 1.373046875
▁value 0.55810546875
▁of 0.01161956787109375
▁$ 0.76904296875
2 1.177734375
0 1.642578125
▁billion 0.2196044921875
▁by 0.130126953125
▁ 0.0251312255859375
2 7.033348083496094e-06
0 3.981590270996094e-05
2 0.350341796875
4 2.3984375
. 0.2330322265625
<0x0A> 0.52099609375
Med 2.765625
Cell 0.06585693359375
▁CE 4.06640625
O 0.000152587890625
, 0.251708984375
▁Dr 1.275390625
. 0.01209259033203125
▁Jonathan 4.6328125
▁Reyn 7.6796875
olds 0.0755615234375
, 0.012725830078125
▁emb 8.4140625
rac 0.169921875
ed 0.006732940673828125
▁the 0.12347412109375
▁positive 1.8251953125
▁reception 2.861328125
▁but 3.80859375
▁acknowled 2.89453125
ged 0.00695037841796875
▁the 0.591796875
▁work 6.4140625
▁that 0.5302734375
▁lies 0.90966796875
▁ahead 0.00025534629821777344
. 0.10400390625
▁" 0.12298583984375
We 0.513671875
▁are 0.341064453125
▁encourag 2.890625
ed 3.7550926208496094e-05
▁by 0.00922393798828125
▁the 0.56298828125
▁initial 1.7080078125
▁results 0.7548828125
▁of 0.478759765625
▁the 1.9013671875
▁On 1.970703125
col 0.0013866424560546875
yn 0.0003540515899658203
▁trial 0.64794921875
▁and 0.89697265625
▁their 7.1796875
▁potential 0.49755859375
▁imp 2.41796875
lications 0.014190673828125
▁for 0.1365966796875
▁cancer 3.25
▁patients 0.290771484375
▁around 3.06640625
▁the 4.1484832763671875e-05
▁world 0.0574951171875
. 0.59716796875
▁However 0.771484375
, 0.0005831718444824219
▁we 0.317138671875
▁understand 3.38671875
▁that 0.421630859375
▁the 2.380859375
▁journey 2.126953125
▁to 0.87939453125
▁regul 1.19921875
atory 4.4465065002441406e-05
▁appro 0.00380706787109375
val 4.76837158203125e-06
▁is 1.47265625
▁a 0.7021484375
▁rig 4.08203125
orous 0.00023031234741210938
▁one 0.38623046875
, 0.62353515625
▁and 0.342041015625
▁we 0.1732177734375
▁remain 0.66357421875
▁committed 0.1715087890625
▁to 0.0004150867462158203
▁further 4.4609375
▁expl 4.3828125
oring 0.257080078125
▁the 0.1900634765625
▁safety 2.955078125
▁and 0.1363525390625
▁effic 0.0294647216796875
acy 6.079673767089844e-06
▁of 0.00756072998046875
▁On 0.6630859375
col 0.0021266937255859375
yn 1.823902130126953e-05
▁in 0.64208984375
▁larger 1.1923828125
▁clin 1.7998046875
ical 9.524822235107422e-05
▁studies 2.818359375
," 0.389404296875
▁he 0.01654052734375
▁stated 1.6455078125
, 4.7421875
▁highlight 3.208984375
ing 0.0001049041748046875
▁the 0.12646484375
▁company 1.30859375
' 0.0036640167236328125
s 6.186962127685547e-05
▁commit 0.56201171875
ment 8.630752563476562e-05
▁to 0.0079803466796875
▁a 5.94921875
▁thorough 1.568359375
▁and 0.78564453125
▁compreh 1.8720703125
ensive 0.00017058849334716797
▁evaluation 0.57421875
▁of 0.51806640625
▁the 0.369384765625
▁drug 0.0293731689453125
' 1.0517578125
s 1.7881393432617188e-05
▁potential 0.320556640625
. 0.094970703125
<0x0A> 0.04852294921875
As 2.044921875
▁Med 1.607421875
Cell 0.005794525146484375
▁Th 0.374267578125
era 1.1324882507324219e-05
pe 2.7298927307128906e-05
ut 1.0132789611816406e-05
ics 0.0002689361572265625
▁prepar 2.234375
es 1.8835067749023438e-05
▁to 0.8095703125
▁advance 2.5546875
▁On 1.1396484375
col 0.00269317626953125
yn 5.173683166503906e-05
▁to 1.818359375
▁the 0.65478515625
▁next 0.06341552734375
▁phase 1.11328125
, 4.0078125
▁medical 4.390625
▁communities 4.765625
▁and 0.947265625
▁patients 1.6025390625
▁are 2.169921875
▁keen 3.697265625
ly 0.211181640625
▁await 0.71484375
ing 0.000530242919921875
▁further 1.984375
▁data 2.087890625
. 2.162109375
▁The 1.6337890625
▁event 7.2265625
ual 0.006622314453125
▁success 2.91796875
▁or 1.1142578125
▁failure 0.007007598876953125
▁of 0.0082244873046875
▁On 1.564453125
col 0.0010137557983398438
yn 5.996227264404297e-05
▁will 0.87548828125
▁und 1.92578125
ou 0.0075225830078125
bt 6.115436553955078e-05
edly 6.556510925292969e-06
▁have 0.81396484375
▁prof 3.591796875
ound 4.76837158203125e-06
▁consequences 2.814453125
▁for 0.213134765625
▁future 4.95703125
▁cancer 0.2371826171875
▁treat 0.9736328125
ments 1.6450881958007812e-05
, 0.783203125
▁the 6.5234375
▁lives 2.298828125
▁of 0.010528564453125
▁count 1.7880859375
less 2.6226043701171875e-06
▁patients 0.414794921875
, 0.09814453125
▁and 0.0057525634765625
▁the 0.04974365234375
▁rapidly 8.453125
▁evol 0.50048828125
ving 5.7220458984375e-06
▁field 1.0751953125
▁of 0.00080108642578125
▁bi 0.20263671875
ote 0.07476806640625
chn 0.0094757080078125
ology 0.0013761520385742188
▁as 2.689453125
▁a 0.0013132095336914062
▁whole 8.726119995117188e-05
. 0.005126953125
